SPRY — ARS Pharmaceuticals, Inc. stock price, charts and financials

QT29ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
5.91
-0.25-4.06%
OverviewShort InterestFilings
SPRYQT29ARS Pharmaceuticals, Inc.·NASDAQ
5.91-4.06%
News
Down 4.1% — ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY (prnewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.33%$15.48MESO+4.96%$16.73ZBIO-1.46%$31.96GHRS-2.07%$29.64TSHA-0.69%$6.51STOK-1.46%$32.23ABCL+31.03%$9.08VRDN-2.29%$23.05
Snapshot
Index-P/E-EPS (ttm)-2.01Insider Own-Shs Outstand99.30MPerf Week20.08%
Market Cap611.71MForward P/E-EPS next Y-0.93Insider Trans-0.06%Shs Float64.50MPerf Month-21.83%
Enterprise Value683.91MPEG0.03EPS next Q-Inst Own-Short Float35.15%Perf Quarter-31.56%
Income-198.01MP/S6.18EPS this Y14.15%Inst Trans-Short Ratio12.41Perf Half Y-36.30%
Sales98.99MP/B9.98EPS next Y46.11%ROA-68.84%Short Interest22.67MPerf YTD-47.12%
Book/sh-P/C-EPS next 5Y-ROE-153.61%52W High17.27 -65.78%Perf Year-65.74%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-85.03%52W Low4.71 25.46%Perf 3Y-12.44%
Dividend Est.-EV/EBITDA-Sales past 3/5Y337.95% 36.08%Gross Margin77.10%Volatility7.06% 6.67%Perf 5Y-79.66%
Dividend TTM-EV/Sales6.91EPS Y/Y TTM-2673.62%Oper. Margin-204.49%ATR (14)0.47Perf 10Y-
Dividend Ex-Date-Quick Ratio4.77Sales Y/Y TTM12.36%Profit Margin-200.00%RSI (14)44.10Recom2.50
Dividend Gr. 3/5Y-Current Ratio4.94EPS Q/Q-74.29%SMA20-0.67%Beta1.05Target Price25.50
Payout0.00%Debt/Eq1.57Sales Q/Q187.50%SMA50-21.86%Rel Volume1.06Prev Close6.16
Employees163LT Debt/Eq0.84EarningsAug 13SMA200-30.52%Avg Volume2.04MPrice5.91
IPO DateDec 04, 2020Option/ShortYes / YesEPS/Sales Surpr.-18.22% 2.17%Net Debt/EBITDA-0.38Volume2,155,067Change-4.06%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-09-26ReiteratedNorthland Securities
Mar-10-26ReiteratedLeerink PartnersOutperform$18
Nov-04-25ResumedRoth CapitalBuy
Sep-26-25ReiteratedRaymond JamesStrong Buy$22
Aug-19-24InitiatedCantor FitzgeraldOverweight
Aug-13-24UpgradeRaymond JamesOutperform → Strong Buy$22
Jul-25-24InitiatedRaymond JamesOutperform$18
Mar-05-24UpgradeLeerink PartnersMarket Perform → Outperform$14 → $18
Sep-20-23DowngradeWilliam BlairOutperform → Market Perform
Dec-13-22InitiatedLeerink Partners$14
Latest News
Today
Today04:44AM
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYprnewswire.com
Aug-08-26
Aug-08-2602:36PM
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Lawbusinesswire.com
Aug-07-26
Aug-07-2606:00PM
Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of an Upcoming Lead Plaintiff Deadline on October 5, 2026newsfilecorp.com
03:20PM
ARS PHARMACEUTICALS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firmglobenewswire.com
12:00PM
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
10:21AM
SPRY Deadline Alert: The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026globenewswire.com
07:21AM
SPRY Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against ARS Pharmaceuticals Inc.prnewswire.com
06:55AM
SPRY SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026newsfilecorp.com
Aug-06-26
Aug-06-2609:00PM
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuitgurufocus.com
06:45PM
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRYprnewswire.com
05:49PM
Rosen Law Firm Urges ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Stockholders with Large Losses to Contact the Firm for Information About Their Rightsbusinesswire.com
03:46PM
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed ARS Pharmaceutic (SPRY)globenewswire.com
03:45PM
Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to a Securities Class Action Deadline on October 5, 2026newsfilecorp.com
12:13PM
SPRY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026globenewswire.com
12:06PM
SPRY INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of ARS Pharmaceuticals, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firmglobenewswire.com
Company

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1008489——————
Cost of Goods Sold Incl. D&A222021——————
Gross Profit766469——————
Selling, General and Administrative Excl. Other2612300——————
Research and Development141320——————
Other Operating Expense4052——————
Operating Income-202-179-3——————
Interest Expense230——————
Unusual Expense
—————————
Non-Operating Income (Expense)71111——————
Net Income Before Taxes-198-1718——————
Income Taxes
000——————
Consolidated Net Income-198-1718——————
Net Income From Continuing Operations-198-1718——————
Net Income-198-1718——————
EPS (Recurring)-2.01-1.740.08——————
EPS (Basic, Before Extraordinaries)-2.01-1.740.08——————
EPS (Diluted)-2.01-1.740.08——————
EBITDA-193-1678——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——135.08——————
Price To Sales Ratio5.8513.7311.50——————
Gross Margin76.0076.1977.53——————
Operating Margin-202.00-213.10-3.37——————
Net Margin-198.00-203.578.99——————
Shares Outstanding999997——————
Market Capitalization5851,1531,023——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$20.33$16.04$11.74$7.44$3.15● Close Price0.00M0.42M0.83M1.25M1.67MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Karas EricChief Commercial OfficerJun 12 '26Option Exercise1.5025,00037,50037,176Jun 12
Karas EricChief Commercial OfficerJun 12 '26Sale10.0025,000250,00012,176Jun 12
Fitzpatrick Alexander AChief Legal OfficerJun 12 '26Sale10.003,35533,55090,910Jun 12
Dorsey BrianChief Operating OfficerNov 13 '25Option Exercise0.6421,82813,97032,617Nov 14
Dorsey BrianChief Operating OfficerNov 13 '25Sale8.7121,828190,05010,789Nov 14
Chakma JustinChief Business OfficerNov 12 '25Option Exercise0.8430,00025,200166,380Nov 14
Chakma JustinChief Business OfficerNov 12 '25Sale8.87166,3801,476,1470Nov 14
Lowenthal Richard EPRESIDENT AND CEOAug 21 '25Sale14.4950,000724,3451,196,494Aug 22
Scott Kathleen D.Chief Financial OfficerAug 21 '25Option Exercise1.5012,50018,75022,542Aug 22
Scott Kathleen D.Chief Financial OfficerAug 21 '25Sale15.0012,500187,50010,042Aug 22
Tanimoto SarinaCHIEF MEDICAL OFFICERAug 20 '25Sale14.0937,656530,6261,247,447Aug 21
Tanimoto SarinaCHIEF MEDICAL OFFICERAug 19 '25Sale14.0312,344173,1301,285,103Aug 21
Karas EricChief Commercial OfficerJul 01 '25Option Exercise1.5015,00022,50025,315Jul 03
Karas EricChief Commercial OfficerJul 01 '25Sale16.9915,000254,86110,315Jul 03
Flynn James E10% OwnerJun 27 '25Sale18.46370,0746,831,5664,887,254Jul 01
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.